VENLAFAXINE XR CAPSULE (EXTENDED RELEASE)
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
30-05-2012
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE)
Fáanlegur frá:
TEVA CANADA LIMITED
ATC númer:
N06AX16
INN (Alþjóðlegt nafn):
VENLAFAXINE
Skammtar:
75MG
Lyfjaform:
CAPSULE (EXTENDED RELEASE)
Samsetning:
VENLAFAXINE (VENLAFAXINE HYDROCHLORIDE) 75MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100/500
Gerð lyfseðils:
Prescription
Lækningarsvæði:
SELECTIVE SEROTONIN AND NOREPINEPHRINE-REUPTAKE INHIBITORS
Vörulýsing:
Active ingredient group (AIG) number: 0131294001; AHFS:
Leyfisstaða:
CANCELLED PRE MARKET
Leyfisdagur:
2015-10-16
Vara einkenni
PRODUCT MONOGRAPH
PR
VENLAFAXINE XR
(venlafaxine hydrochloride extended release capsules)
37.5 mg, 75 mg and 150 mg venlafaxine (as venlafaxine hydrochloride)
Antidepressant / Anxiolytic
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Submission Control No: 155222
Date of Preparation: May 11, 2012
_Page 2_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT
INFORMATION.........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS....................................................................................................5
WARNINGS AND PRECAUTIONS
..................................................................................6
ADVERSE
REACTIONS..................................................................................................19
DRUG INTERACTIONS
..................................................................................................38
DOSAGE AND ADMINISTRATION
..............................................................................43
OVERDOSAGE.................................................................................................................47
ACTION AND CLINICAL
PHARMACOLOGY.............................................................49
STORAGE AND STABILITY
..........................................................................................52
SPECIAL HANDLING
INSTRUCTIONS........................................................................52
DOSAGE FORMS, COMPOSITION AND
PACKAGING..............................................52
PART II: SCIENTIFIC INFORMATION
...............................................................................53
PHARMACEUTICAL
INFORMATION..........................................................................53
CLINICAL TRIALS
..............................................................
Lestu allt skjalið
